Subjective Well Being of Schizophrenic Patients in Greece

AstraZeneca600 enrolled

Overview

Non-interventional study aiming to provide data on the subjective effects of antipsychotic medication assessing subjective well-being and global functioning of patients with Schizophrenia under antipsychotic medication. Moreover it aims to assess their adherence to the treatment and will investigate whether there is any correlation of these factors with the clinical condition of these patients.

Study Type

OBSERVATIONAL

Enrollment

600

Conditions

Schizophrenia

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Provision of written informed consent * Diagnosis of schizophrenia according to DSM-IV * The patient must have been prescribed an atypical antipsychotic for at least 4 weeks before the first study visit Exclusion Criteria: \-

Locations (24)

Research Site

Agrinio, Greece

Research Site

Alexsandroupoli, Greece

Outcomes

Primary Outcomes

Assessment of Subjective well being

Time frame: Relative score reported in SWBN scale at the visit. No baseline comparison

Assessment of functioning

Time frame: Relative score reported in GAF scale at the visit. No baseline comparison

Secondary Outcomes

Assessment of Compliance to therapy

Time frame: Relative score reported in BARS scale at the visit. No baseline comparison

Assessment of General Psychopathology

Time frame: Relative score reported in PANNS scale at the visit. No baseline comparison

Assessment of Clinical Condition

Time frame: Relative score reported in CGIS scale at the visit. No baseline comparison

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.